PHARMABLOCK has systematically laid out AI applications in multiple business areas

On August 11th, PHARMABLOCK stated in its investor relations activity record that the company has systematically laid out AI applications in multiple business areas. In the front-end molecular building block research and development, the technical team applied AI technology to generate over 80 million novel molecular building blocks, effectively addressing structural optimization challenges in new drug design. Since the second half of last year, the screened products have been gradually launched, receiving positive market feedback. In the CDMO process development area, the company has strengthened the collaboration between the process development technical team and the digital intelligence team, widely constructing machine learning models based on high-density data generated from automation to optimize the R&D process and improve process development efficiency. The company will continue to deepen its investment in AI, gradually advancing the deployment of fully automated laboratories and robotic equipment based on the exploration conducted in the initial pilot laboratories